 Rekha Vij
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 18 | 2021 | 216 | 3.880 |
Why?
| | Idiopathic Pulmonary Fibrosis | 15 | 2021 | 144 | 2.330 |
Why?
| | Idiopathic Interstitial Pneumonias | 4 | 2018 | 30 | 1.260 |
Why?
| | Connective Tissue Diseases | 6 | 2018 | 70 | 1.170 |
Why?
| | Autoimmunity | 4 | 2018 | 163 | 0.960 |
Why?
| | Tomography, X-Ray Computed | 12 | 2021 | 2569 | 0.880 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 156 | 0.860 |
Why?
| | Autoimmune Diseases | 4 | 2017 | 233 | 0.810 |
Why?
| | Hypertension, Pulmonary | 4 | 2018 | 340 | 0.710 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2015 | 17 | 0.620 |
Why?
| | Epoprostenol | 1 | 2015 | 54 | 0.610 |
Why?
| | Vascular Resistance | 1 | 2015 | 106 | 0.610 |
Why?
| | Multiple Myeloma | 5 | 2017 | 285 | 0.590 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2015 | 109 | 0.590 |
Why?
| | Carrier Proteins | 1 | 2018 | 685 | 0.570 |
Why?
| | Vasodilator Agents | 1 | 2015 | 180 | 0.560 |
Why?
| | Alveolitis, Extrinsic Allergic | 3 | 2017 | 30 | 0.480 |
Why?
| | Immunosuppressive Agents | 6 | 2019 | 1026 | 0.480 |
Why?
| | Thalassemia | 1 | 2010 | 17 | 0.440 |
Why?
| | Aged | 31 | 2021 | 18500 | 0.430 |
Why?
| | Prevalence | 8 | 2021 | 1263 | 0.420 |
Why?
| | Lung | 5 | 2021 | 1059 | 0.410 |
Why?
| | Retrospective Studies | 20 | 2021 | 7634 | 0.400 |
Why?
| | Pulmonary Fibrosis | 5 | 2019 | 119 | 0.400 |
Why?
| | Middle Aged | 34 | 2021 | 25587 | 0.400 |
Why?
| | Disease Progression | 6 | 2021 | 1470 | 0.390 |
Why?
| | Male | 38 | 2021 | 41881 | 0.390 |
Why?
| | Anemia, Sickle Cell | 1 | 2010 | 129 | 0.380 |
Why?
| | Female | 40 | 2021 | 44762 | 0.380 |
Why?
| | Humans | 49 | 2021 | 83350 | 0.360 |
Why?
| | Lung Diseases | 1 | 2010 | 268 | 0.360 |
Why?
| | Survival Analysis | 10 | 2019 | 1583 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2017 | 812 | 0.360 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 1756 | 0.350 |
Why?
| | Mucin-5B | 2 | 2019 | 13 | 0.350 |
Why?
| | Respiratory Function Tests | 3 | 2018 | 147 | 0.330 |
Why?
| | Acetylcysteine | 2 | 2018 | 76 | 0.320 |
Why?
| | Radiography, Thoracic | 2 | 2018 | 322 | 0.300 |
Why?
| | Prognosis | 11 | 2021 | 3704 | 0.300 |
Why?
| | Cohort Studies | 11 | 2021 | 2708 | 0.270 |
Why?
| | Survival Rate | 9 | 2019 | 1919 | 0.270 |
Why?
| | Rheumatoid Factor | 1 | 2021 | 26 | 0.240 |
Why?
| | Mediastinal Diseases | 1 | 2021 | 24 | 0.230 |
Why?
| | Antibodies, Antinuclear | 2 | 2018 | 88 | 0.230 |
Why?
| | Inhalation Exposure | 1 | 2021 | 28 | 0.220 |
Why?
| | Occupational Health | 1 | 2021 | 34 | 0.220 |
Why?
| | Hematology | 1 | 2020 | 31 | 0.210 |
Why?
| | Telomerase | 1 | 2020 | 56 | 0.210 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 190 | 0.210 |
Why?
| | Occupational Exposure | 1 | 2021 | 75 | 0.210 |
Why?
| | Proportional Hazards Models | 5 | 2018 | 870 | 0.200 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 304 | 0.190 |
Why?
| | Mediastinum | 1 | 2019 | 50 | 0.190 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2020 | 87 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2226 | 0.180 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1367 | 0.180 |
Why?
| | Patient Compliance | 1 | 2020 | 247 | 0.180 |
Why?
| | Free Radical Scavengers | 1 | 2018 | 64 | 0.180 |
Why?
| | Myositis | 1 | 2017 | 17 | 0.180 |
Why?
| | DNA | 2 | 2014 | 1305 | 0.170 |
Why?
| | Pathology, Clinical | 1 | 2017 | 37 | 0.170 |
Why?
| | Transcriptome | 1 | 2021 | 513 | 0.170 |
Why?
| | Prednisone | 1 | 2017 | 264 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2017 | 1185 | 0.160 |
Why?
| | Adult | 19 | 2021 | 25984 | 0.160 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2007 | 108 | 0.160 |
Why?
| | Pulmonary Alveoli | 1 | 2016 | 84 | 0.160 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2020 | 264 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 2 | 2015 | 198 | 0.160 |
Why?
| | Azathioprine | 1 | 2016 | 126 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2017 | 165 | 0.160 |
Why?
| | Graft vs Host Disease | 3 | 2005 | 336 | 0.160 |
Why?
| | Tacrolimus | 1 | 2017 | 384 | 0.150 |
Why?
| | Hospitalization | 2 | 2018 | 766 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2019 | 530 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 343 | 0.140 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 821 | 0.140 |
Why?
| | Bone Resorption | 1 | 2014 | 49 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2100 | 0.140 |
Why?
| | Diphosphonates | 1 | 2014 | 39 | 0.140 |
Why?
| | Telomere Shortening | 1 | 2014 | 24 | 0.140 |
Why?
| | Bone Density Conservation Agents | 1 | 2014 | 48 | 0.140 |
Why?
| | Registries | 4 | 2021 | 662 | 0.140 |
Why?
| | Administration, Oral | 1 | 2015 | 726 | 0.130 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2007 | 265 | 0.130 |
Why?
| | Polymyositis | 1 | 2013 | 7 | 0.130 |
Why?
| | Dermatomyositis | 1 | 2013 | 19 | 0.130 |
Why?
| | Imidazoles | 1 | 2014 | 168 | 0.130 |
Why?
| | Immunity, Innate | 1 | 2017 | 428 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 384 | 0.130 |
Why?
| | Sjogren's Syndrome | 1 | 2013 | 29 | 0.130 |
Why?
| | Scleroderma, Systemic | 1 | 2013 | 40 | 0.130 |
Why?
| | Time Factors | 3 | 2021 | 5496 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2000 | 2313 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 991 | 0.120 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1605 | 0.120 |
Why?
| | Acute Disease | 3 | 2010 | 862 | 0.120 |
Why?
| | Oligopeptides | 1 | 2013 | 186 | 0.120 |
Why?
| | Dyspnea | 1 | 2012 | 80 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2015 | 3877 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2013 | 399 | 0.110 |
Why?
| | Phenotype | 4 | 2020 | 2293 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2020 | 1778 | 0.110 |
Why?
| | Biopsy | 3 | 2021 | 1180 | 0.100 |
Why?
| | Treatment Outcome | 8 | 2019 | 7895 | 0.100 |
Why?
| | Models, Genetic | 1 | 2015 | 923 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 573 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1011 | 0.100 |
Why?
| | Risk Assessment | 4 | 2021 | 2281 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1086 | 0.100 |
Why?
| | African Americans | 1 | 2018 | 1167 | 0.100 |
Why?
| | Breast Neoplasms | 2 | 2000 | 2778 | 0.100 |
Why?
| | United States | 5 | 2021 | 6306 | 0.090 |
Why?
| | Mutation | 3 | 2020 | 3861 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 2079 | 0.090 |
Why?
| | Prospective Studies | 2 | 2021 | 4081 | 0.090 |
Why?
| | Platelet Transfusion | 1 | 2007 | 15 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2021 | 984 | 0.090 |
Why?
| | Lymphocyte Count | 1 | 2007 | 98 | 0.090 |
Why?
| | Cause of Death | 2 | 2019 | 273 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2020 | 359 | 0.080 |
Why?
| | Propensity Score | 2 | 2018 | 131 | 0.080 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2005 | 50 | 0.080 |
Why?
| | Genetic Variation | 1 | 2013 | 1361 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2674 | 0.070 |
Why?
| | Disease-Free Survival | 3 | 2017 | 1196 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1530 | 0.070 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 69 | 0.070 |
Why?
| | Lymphocytes | 1 | 2007 | 477 | 0.070 |
Why?
| | Tachycardia, Supraventricular | 1 | 2004 | 21 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2017 | 373 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 898 | 0.070 |
Why?
| | Recurrence | 2 | 2017 | 1196 | 0.070 |
Why?
| | Chronic Disease | 2 | 2017 | 966 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2000 | 153 | 0.060 |
Why?
| | Asthma | 1 | 2010 | 888 | 0.060 |
Why?
| | Risk | 3 | 2015 | 700 | 0.060 |
Why?
| | Transplantation, Autologous | 2 | 2017 | 331 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 702 | 0.060 |
Why?
| | Antilymphocyte Serum | 1 | 2001 | 86 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2362 | 0.060 |
Why?
| | Life Tables | 1 | 2000 | 51 | 0.060 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2000 | 39 | 0.050 |
Why?
| | Genotype | 2 | 2019 | 1856 | 0.050 |
Why?
| | Leukemia | 2 | 2001 | 300 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2017 | 6576 | 0.050 |
Why?
| | Chicago | 2 | 2017 | 1452 | 0.050 |
Why?
| | Biology | 1 | 2020 | 41 | 0.050 |
Why?
| | Steroids | 1 | 2001 | 175 | 0.050 |
Why?
| | Telomere | 1 | 2020 | 96 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2000 | 307 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2000 | 1682 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2000 | 467 | 0.050 |
Why?
| | Texas | 2 | 2014 | 83 | 0.050 |
Why?
| | Remission Induction | 1 | 2000 | 715 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2000 | 382 | 0.050 |
Why?
| | Mastectomy | 1 | 2000 | 233 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2017 | 25 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2017 | 103 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2017 | 98 | 0.040 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2016 | 24 | 0.040 |
Why?
| | Treatment Failure | 1 | 2017 | 303 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 547 | 0.040 |
Why?
| | Vital Capacity | 1 | 2016 | 60 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 84 | 0.040 |
Why?
| | Fibrosis | 1 | 2017 | 189 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 273 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 1433 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2007 | 159 | 0.040 |
Why?
| | Statistics as Topic | 1 | 2017 | 242 | 0.040 |
Why?
| | Lung Transplantation | 1 | 2018 | 237 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2016 | 414 | 0.040 |
Why?
| | Down-Regulation | 1 | 2017 | 524 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2017 | 297 | 0.040 |
Why?
| | Transplantation, Homologous | 3 | 2005 | 1021 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2017 | 725 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 942 | 0.040 |
Why?
| | Observer Variation | 1 | 2017 | 621 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 962 | 0.040 |
Why?
| | San Francisco | 1 | 2014 | 20 | 0.040 |
Why?
| | Antigens | 1 | 2016 | 270 | 0.040 |
Why?
| | Risk Factors | 2 | 2021 | 5412 | 0.040 |
Why?
| | Logistic Models | 1 | 2018 | 1157 | 0.030 |
Why?
| | Veterans | 1 | 2014 | 55 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 625 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2014 | 48 | 0.030 |
Why?
| | Radiographic Image Enhancement | 1 | 2016 | 466 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2016 | 270 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 453 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 195 | 0.030 |
Why?
| | Signal Transduction | 2 | 2015 | 3300 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 937 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 1331 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 482 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 923 | 0.030 |
Why?
| | Self Report | 1 | 2012 | 262 | 0.030 |
Why?
| | Genomics | 1 | 2015 | 647 | 0.030 |
Why?
| | Neutropenia | 1 | 2007 | 223 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2338 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2005 | 151 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 157 | 0.020 |
Why?
| | Cell Count | 1 | 2005 | 212 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 484 | 0.020 |
Why?
| | Siblings | 1 | 2005 | 112 | 0.020 |
Why?
| | Young Adult | 1 | 2017 | 5968 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2005 | 167 | 0.020 |
Why?
| | Adolescent | 3 | 2005 | 9135 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1924 | 0.010 |
Why?
| | Graft Survival | 1 | 2005 | 884 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2001 | 69 | 0.010 |
Why?
| | Drug Resistance | 1 | 2001 | 266 | 0.010 |
Why?
| | Mastectomy, Modified Radical | 1 | 1999 | 7 | 0.010 |
Why?
| | Oregon | 1 | 1999 | 25 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 1638 | 0.010 |
Why?
| | Washington | 1 | 1999 | 42 | 0.010 |
Why?
| | Tamoxifen | 1 | 1999 | 165 | 0.010 |
Why?
| | Neoadjuvant Therapy | 1 | 1999 | 272 | 0.010 |
Why?
| | Radiotherapy | 1 | 1999 | 338 | 0.010 |
Why?
| | Infant | 1 | 2001 | 3099 | 0.010 |
Why?
| | Child, Preschool | 1 | 2001 | 3756 | 0.010 |
Why?
| | Child | 1 | 2001 | 6759 | 0.010 |
Why?
|
|
Vij's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|